MiNK Therapeutics presents allo-iNKTs combination data in 2L gastric cancer

MiNK Therapeutics (INKT) presented new translational data from its ongoing Phase 2 study of allo-iNKTs, agenT-797, at the American Association for Cancer Research IO Annual Meeting in Los Angeles, California. The study evaluates agenT-797 in combination with botensilimab and balstilimab, in patients with refractory gastroesophageal cancer. Early induction with MiNK’s allogeneic iNKT product, agenT-797, drove broad immune activation-a hallmark of potential durable responses. Investigators report significant increase in interferon-gamma levels, along with enhanced tumor infiltration by T cells and antigen-presenting cells signaling robust systemic immune engagement. These biomarkers typically correlate with improved clinical outcomes and a sustained anti-tumor immune response, reinforcing the potential of this combination in solid cancers. The most pronounced immune expansion and strong peripheral memory T-cell activation were seen when agenT-797 was given concurrently with checkpoint inhibitors and before standard chemotherapy. This underscores the critical importance of treatment sequencing, positioning early allo-iNKT induction as a key driver of therapeutic benefit. Allogeneic, Off-the-Shelf Platform: MiNK’s scalable manufacturing process generates billions of donor-derived iNKT cells in a single run, yielding thousands of doses for rapid global distribution. This approach reduces logistical hurdles and lowers costs, enabling greater patient access worldwide. Differentiated Pipeline: MiNK’s iNKT platform supports expansion into additional hard-to-treat cancers, creating significant opportunities for pipeline breadth, partnerships, and long-term growth.